Antibacterials (ear infection)

Drug Safety Update

January 2021: Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations

Important safety information (for all aminoglycosides)

In view of ototoxicity, the CSM has issued a reminder that treatment with a topical aminoglycoside antibiotic is contraindicated in those with a tympanic (ear drum) performation or patent grommet.

Ciprofloxacin for important safety information for IV/oral use and use by inhalation see Quinolones